Eli Lilly and Company has announced an agreement to acquire Houston-based biotech CrossBridge Bio in a deal valued at up to $300 million, adding an early-stage dual-payload ADC platform to its oncology pipeline. Founded in 2023, CrossBridge is a preclinical company built around technology originating from UTHealth Houston. Key points Total deal value of up […]
Gilead Sciences has announced an agreement to acquire Germany-based clinical-stage biotech Tubulis in a deal valued at up to $5 billion, expanding its oncology pipeline through next-generation antibody-drug conjugate, or ADC, technology. The acquisition adds Tubulis’ lead programme TUB-040, along with its proprietary Tubutecan linker-payload technology and broader ADC platform. The transaction also builds on […]
Last week, Greenstaff Life Sciences attended BIOCHINA2026 in Suzhou, China. Hiroshi Yamaguchi, Head of Greenstaff Life Sciences, and Summer Wang, Director of Greenstaff Medical China, attended the conference and engaged in discussions and exchanges across the life sciences community. Across the event, strong discussions took place around innovation, collaboration, and the future of biotech in […]
In March 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted conditional marketing authorization to two regenerative medicine products derived from induced pluripotent stem cells (iPSCs). The decision represents a significant milestone for the regenerative medicine sector, as these therapies could become the first iPSC-based treatments to receive regulatory approval globally. Since induced pluripotent […]
Gilead Sciences has entered into a definitive agreement to acquire Arcellx for approximately $7.8 billion, securing full ownership of its next-generation CAR-T program. Transaction & Development Overview Total deal value: approximately $7.8B (upfront plus contingent value rights) Lead asset: anitocabtagene autoleucel (anito-cel) BCMA-directed CAR-T therapy Target indication: relapsed/refractory multiple myeloma Clinical studies indicate deep and […]
After a prolonged period of limited public market activity, the US biotech sector saw a notable shift last week. Several biotech companies completed IPOs or filed to go public, collectively raising more than $1 billion. Leading industry media have described this as a selective reopening of the IPO market, rather than a broad-based recovery. Recent […]
Strengthening Early-Stage AML Drug Discovery and Targeted Protein Degradation Capabilities Amgen has announced an agreement to acquire Dark Blue Therapeutics for up to $840 million, reinforcing its strategy to accelerate research and development in acute myeloid leukemia (AML). The transaction includes an upfront payment and development-based milestone payments, subject to customary closing conditions. The acquisition […]
Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for Wegovy®, an oral GLP-1–based therapy indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The decision marks the first FDA approval of an oral GLP-1 receptor agonist for obesity, introducing an alternative to injectable formulations that […]
BioMarin Pharmaceutical has announced that it will acquire Amicus Therapeutics, a company with strong expertise in rare diseases, in an all-cash transaction valued at approximately $4.8 billion.Through this acquisition, BioMarin will add approved therapies for Fabry disease and Pompe disease, significantly expanding its portfolio in the rare disease space. The transaction has attracted attention as […]
Pfizer has officially taken the lead, securing biotech innovator Metsera in a $10 billion agreement that reshapes the competitive landscape for obesity and metabolic therapies. After a week of heavy negotiations, the deal leaves Novo Nordisk on the sidelines and marks Pfizer’s biggest play in the space in years. What’s driving this acquisition A total […]